GeoVax Labs, Inc. (Nasdaq: GOVX) reported financial results for the first quarter of 2026 and provided a business update highlighting continued progress on its GEO-MVA vaccine candidate for mpox and smallpox, as well as strategic developments in its immuno-oncology platform Gedeptin. The company's net loss for the three months ended March 31, 2026, was $5.3 million, compared to $5.4 million in the same period in 2025. Revenue from government contracts was zero in the 2026 period, versus $1.6 million in the prior year, reflecting the termination of a BARDA contract for its COVID-19 vaccine program in April 2025.
GeoVax is focusing its resources on GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine for orthopoxviruses, which is being developed under an expedited regulatory pathway aligned with guidance from the European Medicines Agency (EMA). The company plans to initiate a pivotal Phase 3 immunobridging clinical study expected to enroll approximately 500 participants. The study will evaluate neutralizing antibody responses compared to an approved MVA vaccine, with the goal of demonstrating non-inferiority to support regulatory approval. GeoVax has completed cGMP clinical trial material and initiated CRO selection and trial infrastructure activation.
“GeoVax has strategically aligned the organization around GEO-MVA and the significant global opportunity for a diversified MVA vaccine supply,” said David A. Dodd, Chairman and CEO. “Our efforts are now centered on operational execution of the Phase 3 immunobridging program, supported by completed manufacturing activities, CRO selection, regulatory alignment, and advancing clinical trial initiation.” The company believes GEO-MVA is positioned to address ongoing global supply constraints for orthopoxvirus vaccines, which currently depend on a single foreign supplier. This dependency underscores the importance of establishing additional scalable supply sources for public health preparedness and biodefense resiliency.
In parallel, GeoVax continues to advance its Gedeptin immuno-oncology platform, a gene-directed enzyme prodrug therapy designed to enhance checkpoint inhibitor activity in solid tumors. The company recently entered into an exclusive license agreement with Emory University covering intellectual property related to Gedeptin in combination with immune checkpoint inhibitors. GeoVax believes Gedeptin’s localized tumor-targeting mechanism may help convert immunologically “cold” tumors into more responsive microenvironments, aligning with the broader industry shift toward combination immunotherapy approaches.
Financially, GeoVax reported cash and cash equivalents of $1.3 million as of March 31, 2026, down from $3.1 million at December 31, 2025. Research and development expenses decreased to $3.9 million from $5.4 million in the prior-year quarter, primarily due to lower costs associated with discontinued BARDA activities and reduced spending on its COVID-19 vaccine program. General and administrative expenses declined to $1.4 million from $1.7 million, driven by lower investor relations costs and stock-based compensation.
The company’s strategic prioritization places primary emphasis on GEO-MVA, reflecting established MVA platform validation, expedited regulatory alignment, and large existing and anticipated orthopoxvirus vaccine demand. GeoVax also sees potential long-term opportunities in scalable manufacturing through its continuous cell-line manufacturing initiatives utilizing the AGE1 platform. The combination of GEO-MVA and Gedeptin positions GeoVax within two strategically important healthcare sectors: biosecurity preparedness and immunotherapy. For more information, visit www.geovax.com.
